Akèy › Makroglobulinemi Waldenstrom
Etid klinik pou Makroglobulinemi Waldenstrom ap rekrite nan Etazini
29 etid pou Makroglobulinemi Waldenstrom ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Durham, NC10 etid
- Boston, MA9 etid
- Denver, CO7 etid
- New York City, NY6 etid
- Edison, NJ6 etid
- Dallas, TX6 etid
- Houston, TX6 etid
- Milwaukee, WI5 etid
- Rochester, MN5 etid
- Seattle, WA5 etid
- Columbus, OH4 etid
- Baldwin Park, CA4 etid
- Queens, NY4 etid
- Washington, DC4 etid
- Chicago, IL4 etid
- Salt Lake City, UT3 etid
- Cincinnati, OH3 etid
- Richmond, VA3 etid
- Philadelphia, PA3 etid
- Cleveland, OH3 etid
- Portland, OR3 etid
- Jacksonville, FL3 etid
- Miami, FL3 etid
- Nashville, TN3 etid
Pa eta
- Arizona4 etid
- Colorado8 etid
- Florid7 etid
- Georgia3 etid
- Illinois5 etid
- Iowa3 etid
- Kalifòni11 etid
- Maryland5 etid
- Massachusetts11 etid
- Michigan5 etid
- Minnesota5 etid
- New Jersey7 etid
- New York8 etid
- North Carolina12 etid
- Ohio8 etid
- Oregon3 etid
- Pennsylvania3 etid
- Tennessee3 etid
- Texas11 etid
- Utah3 etid
- Virginia3 etid
- Washington7 etid
- Wisconsin6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07231952Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Sep 28, 2026 · NCT00923507A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT04728893Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT04840602A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT06561347A Study of ARC-02 in B-cell NHL
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06340737Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT07426484Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT05640102A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06708897A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07424833A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT06860880Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 7, 2026 · NCT02269592SynKIR-310 for Relapsed/Refractory B-NHL
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 14, 2026 · NCT06544265A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137Epcoritamab in Previously Treated WM
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT06510491Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Feb 27, 2026 · NCT06151730Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT04775745Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT05602363A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 5, 2025 · NCT06986174Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.